In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

Acute coronary syndromes for the rest of us: a quick practical review of the ESC Guidelines

ESC webinar

Add to calendar21/02/20120:00 21/02/20120:00 Europe/Paris Acute coronary syndromes for the rest of us: a quick practical review of the ESC Guidelines European Society of Cardiology DD/MM/YYYY
Acute Coronary Syndromes (ACS)
Cardiovascular Pharmacology and Pharmacotherapy
Chronic Ischaemic Heart Disease (IHD)
Acute Cardiac Care

 View the webinar recording


Jose Lopez-Sendon and Gerasimos Fillipatos

Content of the course

  • Algorythm for chest pain diagnosis suspected of cardiac origin
  • STEMI diagnosis, Primary PCI and Trombolysis
  • Risk scores
  • Algorythm for invasive vs conservative strategies
  • Coadjuvant therapy. Anticoagulation and antiagregation


Key references

ESC STEMI  guidelines 2008
ESC non-STEACS guidelines 2011


Professor Lopez-Sendon answers your questions...

Questions Answers
Would you use upstream Gp IIb/IIIa Inhibitors for this patient (before the cath lab)? Thank you for your question : No. I  There is not benefit demonstrated for IIb-IIa inh in this patines. Nowdays, with new antocoagulant (e.g bivalirudin) and oral antoagragants (prasugrel, ticagrelor), it is difficult to find an indication for IIb-IIIa antagonists.
Regarding risk stratification, do you always assess bleeding risk (for example CRUSADE score) at admission in every ACS patient? We should. But in practice, what we actually do is to assess contraindications for anticoagulation
Regarding the coadjuvant therapy: do you use a "loading dose" of statin before sending the patient to the cath lab? (following the evidence from NAPLES II and ARMYDA RECAPTURE trials) No, but is not a bad idea. We should 
If you have in your hospital both ticagrelor and prasugrel, when do you use prasugrel (instead of ticagredor)? We only have prasugrel. Should we have noth I think prasugrel will be the first choice for patients going directly to the cath lab (STEMI, very unstable NonSTE ACS)
Will we have a copy of the slides? I think you can download the slide set from the ESC webpage 
In your clinical practice, do you test clopidogrel's platelet reactivity with platelet function tests? When? In which patients?  No, never, but some, people (mainly cath lab people) do